​May is Melanoma and Skin Cancer Awareness Month! We have much information on skin cancer, melanoma (the most serious and dangerous type of skin cancer), sunscreens, tanning beds and melanoma risk, sun protection, and much more on our website (simply select any of our articles you'd like to read from the list) and on our Youtube channel. 
​
#MelanomaAwarenessMonth #SkinCancerAwarenessMonth 

​#may #skincancer #melanoma #tanningbed #solarium #cancer #cancerawareness #cancerprevention #cancereducation #cancerpatients #cancersurvivors #sunscreens #sunblock #sunprotection #health #healthylifestyle

May is Brain Cancer Awareness Month! We have much information on brain cancer, including glioblastoma multiforme (GBM), the most aggressive and deadly type of brain cancer in adults, FDA approvals, news, wireless phones and much more on our website. Simply select any of our articles you'd like to read. 

Also, don't forget to get our handmade CERI Brain Cancer Awareness Scarf, in memory or in honor of your loved ones, or simply show support to our cancer programs. We have only 2 items left - so, get your scarf today on our online store.  

#canceredinstitute 

May 9 is National Women's Check-Up Day! We have much information on breast, cervical, and ovarian cancers as well as on thermography on our website at canceredinstitute.org and on our youtube channel at youtube.com/canceredinstitute. 
Doing your regular check-ups is very important not only for early detection of cancer, but also for 'any' disease. 
_____

Don't forget to follow us @canceredinstitute #canceredinstitute 
and subscribe to our youtube channel, don't miss our cancer videos: youtube.com/canceredinstiute 

#nationalwomenscheckupday #may #cancerawareness #womenshealth #checkup #health #checkupday #breastcancer #cancer #ovariancancer #cervicalcancer #thermography #ultrasound #mammogram #earlydetection #earlydetectionofcancer #cancerdiagnosis #earlydiagnosis

The study has been published today, May 2, 2019 in the scientific journal Genes & Development.

Corresponding author of this study is Dr. Diane Simeone: diane.simeone@nyulangone.org

#breakingnews #breakthrough #science #sciencenews #cancerresearch #pancreaticcancer #cancer #cancerresearch #genes #newyorkuni #nyulangone #umich #umichigan #newyork #michigan #langone #hope #pancreaticcancerawareness

Young women who regularly drink alcohol before their first pregnancy may be increasing their risk for breast cancer study published in The Journal of the National Cancer Institute reports. The study says that the "breast tissue is particularly susceptible to carcinogens between menarche and first full-term pregnancy". 

This report is the conclusion of a 20-year study, summerizing data from 91,005 parous women. 

The report concludes that "Alcohol consumption before first pregnancy was consistently associated with increased risks of proliferative benign breast disease (BBD) and breast cancer."

References: 

1. J Natl Cancer Inst;2013;105:1571–1578
2. The New York Times, 9/6/2013. 
   

#breastcancer #driking #womendrinking #breastcancerrisk #cancerrisk #drinkingandcancerrisk #drinkingandbreastcancerrisk #alcohol #effectsofalcohol #health #cancer #breastcancerawareness #cancerawreness #breastcancerawarenessmonth #BCAM #cancerprevention #cancereducation #canceredinstitute 

Today is World Cancer Day! Help us to raise awareness for Cancer and the importance of cancer education - become a CERI Golden Hearts member today!
http://www.canceredinstitute.org/membership.html

#WorldCancerDay #Cancer #patienteducation #publiceducation #cancereducation #cancerawareness #canceredinstitute

Read the scientific article entitled Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells here.

To learn more about Acute Lymphoblastic Leukemia (ALL), read our article here.   

​#leukemia #ALL #AcuteLymphoblasticLeukemia #CAR #CARTCells #immunesystem #geneengineering #TALEN #Crispr #geneediting #universalTcells #universalimmunecells #childhoodleukemia #cchildhoodcancer #universitycollegelondon #cancerresearch #cancertreatment #cancer #cancereducation #patientenducation #publiceducation #canceredintitute 

Researchers from Ruhr-University in Bochum, Germany, treated human samples of breast cancer cells with Capsaicin to dissect its ability to destroy them. They found that Capsaicin induces apoptosis (cell death) in cancer cells. When capsaicin reaches a cancer cell, it attaches to the cell surface and switches on a cell receptor, a protein expressed/produced on the cell surface, called TRPV1. The receptor TRPV1 is a calcium/sodium channel that controls them go in and out of the cancer cell. When TRPV1 is switched on by capsaicin, the cancer cell is sent into overdrive and starts to self-destruct by induced apoptosis (programmed cell death). The researchers have found a significant reduction in cell proliferation after capsaicin stimulation was observed.This study was carried out by scientists from:

• Ruhr-University in Bochum, Germany
• Hospital Herz-Jesu-Krankenhaus Dernbach, Germany
• Centre of Genomics in Cologne, Germany

Read more here in the news, and the original scientific article, Expression and functionality of TRPV1 in breast cancer cells, here.

University College London Hospitals (UCLH) researchers used a light-sensitive drug, which is injected into the bloodstream. A laser then activates the drug, which eradicates tumor tissue in the prostate. This new treatment is called vascular-targeted photodynamic therapy, or VTP. 

Published in The Lancet Oncology, the study showed that 49 percent of patients given VTP went into ‘complete remission’ compared with 13.5 percent of patients in the control group.

The scientific title of the study is called 'Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial'

Read more on CNBC's website:
www.cnbc.com/2016/12/20/a-new-form-of-therapy-involving-lasers-could-transform-the-way-prostate-cancer-is-treated.html

Read the scientific article on The Lancet Oncology's website:
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30661-1/fulltext

​FDA approves today Rubraca (rucaparib) to treat women with advanced ovarian cancer that has BRCA gene mutation. 

BRCA genes are involved with repairing damaged DNA. Thus, under normal conditions, they work to prevent tumor development. However, mutations (abnormalities) of these genes may lead to certain cancers, which include breast and ovarian cancers. Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme (a protein involved in catalytic reactions in our body), which is involved in repairing damaged DNA. By blocking this enzyme through Rubraca, DNA inside the cancerous cells with damaged/mutated/abnormal BRCA genes may be less likely to be repaired by the enzyme, which leads to cell death and potentially a slow-down or inhibition of tumor growth.

Common side effects of Rubraca include nausea, fatigue, vomiting, low levels of red blood cells (anemia), abdominal pain, unusual taste sensation (dysgeusia), constipation, decreased appetite, diarrhea, low levels of blood platelets (thrombocytopenia) and trouble breathing (dyspnea).  Rubraca is associated with serious risks, such as bone marrow problems (myelodysplastic syndrome), a type of cancer of the blood called acute myeloid leukemia and fetal harm.

Rubraca is marketed by Clovis Oncology, Inc. based in Boulder, Colorado. The FoundationFocus CDxBRCA companion diagnostic is marketed by Foundation Medicine, Inc. of Cambridge, Massachusetts.

For more information visit the FDA's website: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm